[A case of recurrent uterine cervical cancer successfully treated with etoposide].
A 69 year-old woman with recurrent uterine cervical cancer was treated by etoposide because of ascites retention and elevated serum SCC level. The etoposide (50 mg/day, for 14 consecutive days followed by 2-week suspension by oral administration) was given for 8 months and more. After 3 months of treatment, a complete response has been found by echography (disappearance of ascites and negative intraperitoneal smear test) and the serum SCC level became normal at 0.8 ng/ml from 4.1 ng/ml prior to treatment. No particular side effects were found in this patient during treatment. These results demonstrate that etoposide (cyclic per os therapy) may be effective for the patient with recurrent uterine cervical cancer, and this treatment could be acceptable in the outpatient department.
Kobayashi
H
H
Dept. of Obstetrics and Gynecology, Hamamatsu University School of Medicine.
Kawashima
Y
Y
D000284:Administration, Oral; D000368:Aged; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D005047:Etoposide